Astrazeneca (AZN) Cash from Financing Activities (2009 - 2026)

Astrazeneca (AZN) has reported Cash from Financing Activities for 17 consecutive years, with $267.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 109.86% year-over-year to $267.0 million; the TTM figure through Mar 2026 stood at -$4.6 billion (up 62.09% YoY), while the FY2025 annual figure was -$7.5 billion, down 88.79% from the prior year.
• Cash from Financing Activities came in at $267.0 million for Q1 2026 at Astrazeneca, up from -$3.3 billion in the prior quarter.
• The five-year high for Cash from Financing Activities was $2.0 billion in Q1 2024, with the low at -$6.6 billion in Q4 2023.
• Average Cash from Financing Activities over 5 years is -$2.4 billion, with a median of -$2.1 billion recorded in 2025.
• Across the five-year window, Cash from Financing Activities jumped 199.85% in 2024 and slumped 233.48% in 2025, its largest moves.
• Year by year, Cash from Financing Activities stood at -$6.5 billion in 2022, then dropped by 1.58% to -$6.6 billion in 2023, then jumped by 39.15% to -$4.0 billion in 2024, then grew by 17.87% to -$3.3 billion in 2025, then jumped by 108.14% to $267.0 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $267.0 million, -$3.3 billion, and -$2.1 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.